Estimated biologic CDMO pharma market trends
With an increasing demand for novel therapeutics, the global CDMO biologic market was estimated to increase from $1.3 billion in 2021 to $3.1 billion in 2030, according to Prescient & Strategic Intelligence.1 Technavio estimates an $8.65 billion growth between 2021 to 2026, with a large percentage of growth originating in the US and Canada.2 Major contributors to the market revenue will be drug substances and mammalian cell culture.1,2 Grand View Research estimates a CDMO market growth of up to $157.7 billion in 2025 and a compound annual growth rate of 6.9%, in which this growth rate will supersede the pharmaceutical industry.3 The expected boom in the CDMO market can also be attributed to the increased willingness to outsource therapeutic manufacturing to streamline the time to market, decrease costs, and reallocate internal resources.
Understanding the CDMO services you need
CDMO services can span from the beginning of a project with drug discovery & preclinical stages through the commercial stage, which includes manufacturing. Although the services at each stage are critical, drug product development and GMP manufacturing services will carry more weight within a market saturated with similar therapeutic competitors.4 It is all too common that a “manufacturability” assessment that should have been incorporated in the drug development workflow is overlooked to reduce the initial cost and increase speed, but that time and money saved (and possibly more) will most likely come at a cost during manufacturing.